Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform dec...
In the pharmaceutical field, the term ‘fourth hurdle ’ hasbecome common currency in many health syst...
AbstractDecisions about which health-care interventions represent adequate value to collectively fun...
[INTRODUCTION] Licensing is the main method of regulating and controlling access to pharmaceuticals....
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to...
There are three known criteria that underlie drug reimbursement decisions: therapeutic value, cost e...
A concern to contain the costs of providing equality of access to prescription medicines while prese...
The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceu...
Objectives: This study outlines the needs and current development of the "fourth hurdle" (i.e., requ...
Pharmaceutical regulators and healthcare reimbursement authorities operate in different intellectual...
<div><p>Background</p><p>Advances in pharmaceuticals offer improved health outcomes for a wide range...
New products evolving from research and development can only be translated to medical practice on a ...
Introduction: There is continued unmet medical need for new medicines across countries especially fo...
AbstractThe global prescription medicines industry argues that it needs high prices for new medicine...
Advances in pharmaceuticals offer improved health outcomes for a wide range of illnesses, yet medici...
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform dec...
In the pharmaceutical field, the term ‘fourth hurdle ’ hasbecome common currency in many health syst...
AbstractDecisions about which health-care interventions represent adequate value to collectively fun...
[INTRODUCTION] Licensing is the main method of regulating and controlling access to pharmaceuticals....
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to...
There are three known criteria that underlie drug reimbursement decisions: therapeutic value, cost e...
A concern to contain the costs of providing equality of access to prescription medicines while prese...
The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceu...
Objectives: This study outlines the needs and current development of the "fourth hurdle" (i.e., requ...
Pharmaceutical regulators and healthcare reimbursement authorities operate in different intellectual...
<div><p>Background</p><p>Advances in pharmaceuticals offer improved health outcomes for a wide range...
New products evolving from research and development can only be translated to medical practice on a ...
Introduction: There is continued unmet medical need for new medicines across countries especially fo...
AbstractThe global prescription medicines industry argues that it needs high prices for new medicine...
Advances in pharmaceuticals offer improved health outcomes for a wide range of illnesses, yet medici...
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform dec...
In the pharmaceutical field, the term ‘fourth hurdle ’ hasbecome common currency in many health syst...
AbstractDecisions about which health-care interventions represent adequate value to collectively fun...
DOI
Add to ORKG